Effects of pre- and postnatal haloperidol administrations to pregnant and nursing rats on brain catecholamine levels in their offspring.
Effects of perinatal, maternal treatments with haloperidol on brain catecholamine and serotonin concentrations in maturing offspring were examined. The drug was administered orally, at three different dosages, each day from the 14th gestational day to postnatal day 12. At 14, 22, 53 and 90 days of age offspring were selected for regional assays of amine neurotransmitter concentrations. The results indicate that haloperidol can alter the developmental accumulation of central catecholaminergic neurotransmitters. The drug-induced decreases in cortical and spinal norepinephrine levels and in striatal dopamine content in the offspring persisted into adulthood. Regional serotonin concentrations in offspring were not affected by the maternal haloperidol treatments. These findings suggest that central catecholamine receptors are necessary for normal development of dopaminergic and noradrenergic innervation in the central nervous system.
D000375:Aging; D000818:Animals; D000833:Animals, Suckling / Q000378:metabolism; D001921:Brain / Q000254:growth & development; D001923:Brain Chemistry / Q000187:drug effects*; D002395:Catecholamines / Q000378:metabolism*; D004298:Dopamine / Q000378:metabolism; D005260:Female; D006220:Haloperidol / Q000494:pharmacology*; D009638:Norepinephrine / Q000378:metabolism; D011247:Pregnancy; D011270:Pregnancy, Animal / Q000187:drug effects*; D051381:Rats; D011919:Rats, Inbred Strains; D012701:Serotonin / Q000378:metabolism; D013116:Spinal Cord / Q000187:drug effects / Q000378:metabolism; D013997:Time Factors
D002395:Catecholamines; D012701:Serotonin; D006220:Haloperidol; D004298:Dopamine; D009638:Norepinephrine